POLY MEDICURE LTD. - 531768 - Announcement under Regulation 30 (LODR)-Investor Presentation
Dear Sir/Madam, Please find enclosed the Investor Presentation covering the performance highlights of the Company for Q3 of FY 2020-21. We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. POLY MEDICURE LTD. - 531768 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the officials of the Company will participate in the investors meeting. We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Buy Poly Medicure; target of Rs 620: Dolat Capital Market
Dolat Capital Market is bullish on Poly Medicure has recommended buy rating on the stock with a target price of Rs 620 in its research report dated January 27, 2021. POLY MEDICURE LTD. - 531768 - Compliance Of Regulation 30 And 33 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dear Sir/Madam, In continuation of the Company's unaudited standalone and consolidated financial results along with Limited Review Report for the quarter and nine months ended on 31st December, 2021 ('the Results') filed with stock exchanges on 27th January, 2021, please be informed that the Company has also adopted the interim condensed consolidated financial statements for the Nine months ended December 31, 2020 which is also available on the Company's website under the 'Investor Information' section. We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Thanking You,
POLY MEDICURE LTD. - 531768 - Outcome Of The Board Meeting Of The Company
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 27th January, 2021, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Standalone and Consolidated Un-Audited Financial Results along with Limited Review Report for the quarter and Nine Months ended on 31st December, 2020; and b) Any other businesses. We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Thanking You, POLY MEDICURE LTD. - 531768 - Outcome Of The Board Meeting Of The Company
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 27th January, 2021, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Standalone and Consolidated Un-Audited Financial Results along with Limited Review Report for the quarter and Nine Months ended on 31st December, 2020; and b) Any other businesses. We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Thanking You, POLY MEDICURE LTD. - 531768 - Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 27Th January, 2021
POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2021 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday, the 27th January, 2021, inter alia to consider the following: a) To consider and approve the Un-Audited Financial Results of the Company for the Third quarter and Nine months ended on 31st December, 2020. b) To transact any other matter which the Board may deem fit. This is for your information and record. POLY MEDICURE LTD. - 531768 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Poly Medicure Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here POLY MEDICURE LTD. - 531768 - Intimation Of Voting Results Of Postal Ballot As Per Regulation 44(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We wish to inform you that, in compliance with applicable Regulations of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 as amended and other applicable laws, the shareholders of the Company have approved the Special Resolutions for the aforesaid matters by requisite majority on January 14, 2021, through remote e-voting postal ballot process as set out in the postal ballot notice. Pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, details of the voting results of the Postal Ballot declared on January 14, 2021 are enclosed in the prescribed format along with the Scrutinizer Report on remote e-voting postal ballot as received by the Company and results are being uploaded on website of Stock Exchange in XBRL Mode.